{"protocolSection":{"identificationModule":{"nctId":"NCT05246514","orgStudyIdInfo":{"id":"D7811C00001"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","officialTitle":"An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05)","acronym":"DL-05"},"statusModule":{"statusVerifiedDate":"2025-07","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-07-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-09-23","type":"ACTUAL"},"completionDateStruct":{"date":"2026-03-16","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-02-11","studyFirstSubmitQcDate":"2022-02-11","studyFirstPostDateStruct":{"date":"2022-02-18","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-09-04","resultsFirstSubmitQcDate":"2024-11-27","resultsFirstPostDateStruct":{"date":"2024-12-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-08-08","lastUpdatePostDateStruct":{"date":"2025-08-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"},"collaborators":[{"name":"Daiichi Sankyo","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC."},"conditionsModule":{"conditions":["HER2-mutant Non-Small Cell Lung Cancer"],"keywords":["DL05","T-DXd","HER2-mutant Non-Small Cell Lung Cancer","NSCLC","Trastuzumab deruxtecan","ERBB2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":72,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"T-DXd arm","type":"EXPERIMENTAL","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle.","interventionNames":["Drug: Trastuzumab deruxtecan"]}],"interventions":[{"type":"DRUG","name":"Trastuzumab deruxtecan","description":"administered as an IV infusion","armGroupLabels":["T-DXd arm"],"otherNames":["T-DXd, DS-8201a"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"ICR-assessed ORR (Objective Response Rate)","description":"Confirmed ORR, defined as the percentage of participants with confirmed complete response or partial response, as assessed by independent central review(ICR) based on RECIST 1.1.","timeFrame":"At an average of approximately 14 months"}],"secondaryOutcomes":[{"measure":"Investigator-assessed ORR (Objective Response Rate)","description":"Confirmed ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1","timeFrame":"An average of approximately 14 months"},{"measure":"ICR-assessed and Investigator-assessed DoR (Duration of Response)","description":"DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.","timeFrame":"At an average of approximately 14 months"},{"measure":"ICR-assessed and Investigator-assessed DCR (Disease Control Rate)","description":"DCR is the percentage of participants who achieved confirmed CR, PR, or SD during study intervention.","timeFrame":"Approximately 6 weeks"},{"measure":"ICR-assessed and Investigator-assessed PFS (Progression-free Survival)","description":"PFS is the time from date of enrolment until first objective radiographic tumour progression or death from any cause.","timeFrame":"An average of approximately 14 months"},{"measure":"OS (Overall Survival)","description":"OS is the time from date of enrolment until death from any cause.","timeFrame":"An average of approximately 22 months"},{"measure":"ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival)","description":"CNS-PFS is the time from date of enrolment until CNS tumour progression per RECIST 1.1 as assessed by ICR due to any cause in the absence of CNS progression.","timeFrame":"An average of approximately 14 months"},{"measure":"Serum Concentrations of T-DXd","description":"Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd.","timeFrame":"An average of approximately 14 months"},{"measure":"Serum Concentrations of Total Anti-HER2 Antibody","description":"Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for total anti-HER2 antibody.","timeFrame":"An average of approximately 14 months"},{"measure":"Serum Concentrations of DXd","description":"Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for DXd.","timeFrame":"An average of approximately 14 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically documented metastatic non-squamous NSCLC.\n* Has relapsed from or is refractory to at least one-line of anticancer treatment.\n* Documented HER2 exon 19 or 20 mutation from central FFPE tumour tissue testing.\n* WHO or ECOG performance status of 0 or 1.\n* Presence of at least one measurable lesion assessed by the investigator based on RECIST 1.1.\n* LVEF ≥ 50% within 28 days before enrolment.\n\nExclusion Criteria:\n\n* Mixed small cell lung cancer, squamous histology NSCLC, and sarcomatoid histology variant NSCLC.\n* Corrected QT interval (QTcF) prolongation to \\> 470 ms (females) or \\> 450 ms (males), based on average of the screening triplicate 12-lead ECG.\n* History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.\n* Has unresolved toxicities from previous anticancer therapy, defined as toxicities (excluding alopecia) not yet resolved to Grade ≤1 or baseline. Participants with clinically stable chronic Grade 2 toxicity not reasonably expected to be exacerbated by study intervention may be included only after consultation with the AstraZeneca study physician or designee.\n* Has been previously treated with HER2-targeted therapies, except for pan-HER class TKIs or has received prior treatment with an ADC which consists of an exatecan derivative that is a topoisomerase I inhibitor.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Research Site","city":"Baoding","zip":"071000","country":"China","geoPoint":{"lat":38.87288,"lon":115.46246}},{"facility":"Research Site","city":"Beijing","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Beijing","zip":"100191","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Changchun","zip":"130000","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Research Site","city":"Changsha","zip":"410008","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Research Site","city":"Changsha","zip":"410013","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Research Site","city":"Chengdu","zip":"610041","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Research Site","city":"Chongqing","zip":"400030","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Research Site","city":"Guangzhou","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Research Site","city":"Guangzhou","zip":"510515","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Research Site","city":"Hangzhou","zip":"310020","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Research Site","city":"Hangzhou","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Research Site","city":"Harbin","zip":"150081","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Research Site","city":"Hefei","zip":"133500","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"Research Site","city":"Hefei","zip":"230601","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"Research Site","city":"Linyi","zip":"276000","country":"China","geoPoint":{"lat":35.06306,"lon":118.34278}},{"facility":"Research Site","city":"Nanjing","zip":"210029","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Research Site","city":"Shandong","country":"China","geoPoint":{"lat":26.82656,"lon":114.95747}},{"facility":"Research Site","city":"Shanghai","zip":"200025","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Research Site","city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Research Site","city":"Shenyang","zip":"110042","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Research Site","city":"Shenzhen","zip":"518020","country":"China","geoPoint":{"lat":22.54554,"lon":114.0683}},{"facility":"Research Site","city":"Wuhan","zip":"430022","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Research Site","city":"Wuhan","zip":"430060","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Research Site","city":"Xi'an","zip":"710061","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Research Site","city":"Xiamen","zip":"361003","country":"China","geoPoint":{"lat":24.47979,"lon":118.08187}},{"facility":"Research Site","city":"Yangzhou","zip":"225001","country":"China","geoPoint":{"lat":32.39722,"lon":119.43583}},{"facility":"Research Site","city":"Zhengzhou","zip":"450000","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Redacted CSP","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D7811C00001&amp;attachmentIdentifier=4aca569e-8f50-4761-90f5-52f8b9212e55&amp;fileName=d7811c00001-csp-v2_sign-off_version_Redacted_PDFA.pdf&amp;versionIdentifier="},{"label":"Redacted SAP","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D7811C00001&amp;attachmentIdentifier=68e28558-1517-42b2-8680-e6d7c9bbccec&amp;fileName=d7811c00001-sap-ed-2_8Aug2024_Redacted_PDFA.pdf&amp;versionIdentifier="},{"label":"Redacted CSR synopsis","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D7811C00001&amp;attachmentIdentifier=71ebc875-bf50-46e2-8717-039305429672&amp;fileName=D7811C00001_-___Primary_Clinical_Study_Report_Synopsis_Redacted_PDFA.pdf&amp;versionIdentifier="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.","infoTypes":["STUDY_PROTOCOL"],"timeFrame":"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","accessCriteria":"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","url":"https://astrazenecagroup-dt.pharmacm.com/DT/Home"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"72"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"72"}]}],"dropWithdraws":[{"type":"Ongoing in the study at data cut-off date","reasons":[{"groupId":"FG000","numSubjects":"58"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"13"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"72"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.0","lowerLimit":"34","upperLimit":"76"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.4","spread":"9.74"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"41"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"31"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"72"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"72"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"ICR-assessed ORR (Objective Response Rate)","description":"Confirmed ORR, defined as the percentage of participants with confirmed complete response or partial response, as assessed by independent central review(ICR) based on RECIST 1.1.","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At an average of approximately 14 months","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","lowerLimit":"46.1","upperLimit":"69.8"}]}]}]},{"type":"SECONDARY","title":"Investigator-assessed ORR (Objective Response Rate)","description":"Confirmed ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"An average of approximately 14 months","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","lowerLimit":"46.1","upperLimit":"69.8"}]}]}]},{"type":"SECONDARY","title":"ICR-assessed and Investigator-assessed DoR (Duration of Response)","description":"DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.","populationDescription":"Full analysis set (patients with confirmed objective response included in the analysis)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"At an average of approximately 14 months","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"title":"ICR-assessed","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"6.1","upperLimit":"NA","comment":"NA - Not calculated, estimate cannot be calculated as the median time frame was not reached. Insufficient number of participants with events for median and upper limit of 95% confidence interval."}]}]},{"title":"Investigator-assessed","categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"7.2","upperLimit":"NA","comment":"NA - Not calculated, estimate cannot be calculated. Insufficient number of participants with events for upper limit of 95% confidence interval."}]}]}]},{"type":"SECONDARY","title":"ICR-assessed and Investigator-assessed DCR (Disease Control Rate)","description":"DCR is the percentage of participants who achieved confirmed CR, PR, or SD during study intervention.","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Approximately 6 weeks","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"title":"ICR-assessed","categories":[{"measurements":[{"groupId":"OG000","value":"91.7","lowerLimit":"82.7","upperLimit":"96.9"}]}]},{"title":"Investigator-assessed","categories":[{"measurements":[{"groupId":"OG000","value":"93.1","lowerLimit":"84.5","upperLimit":"97.7"}]}]}]},{"type":"SECONDARY","title":"ICR-assessed and Investigator-assessed PFS (Progression-free Survival)","description":"PFS is the time from date of enrolment until first objective radiographic tumour progression or death from any cause.","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"An average of approximately 14 months","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"title":"ICR-assessed","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"7.2","upperLimit":"NA","comment":"NA - Not calculated, estimate cannot be calculated as the median PFS time was not reached. Insufficient number of participants with events for median and upper limit of 95% confidence interval."}]}]},{"title":"Investigator-assessed","categories":[{"measurements":[{"groupId":"OG000","value":"10.8","lowerLimit":"7.2","upperLimit":"NA","comment":"NA - Not calculated, estimate cannot be calculated. Insufficient number of participants with events for upper limit of 95% confidence interval."}]}]}]},{"type":"SECONDARY","title":"OS (Overall Survival)","description":"OS is the time from date of enrolment until death from any cause.","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"An average of approximately 22 months","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"NA - Not calculated, estimate cannot be calculated as the median OS was not reached. Insufficient number of participants with events for median and lower and upper limits of 95% confidence interval."}]}]}]},{"type":"SECONDARY","title":"ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival)","description":"CNS-PFS is the time from date of enrolment until CNS tumour progression per RECIST 1.1 as assessed by ICR due to any cause in the absence of CNS progression.","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"An average of approximately 14 months","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"7.8","upperLimit":"NA","comment":"NA - Not calculated, estimate cannot be calculated as the median CNS-PFS was not reached. Insufficient number of participants with events for median and upper limit of 95% confidence interval."}]}]}]},{"type":"SECONDARY","title":"Serum Concentrations of T-DXd","description":"Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd.","populationDescription":"PK analysis set","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"An average of approximately 14 months","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"title":"Cycle 1 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"NA - Not calculated, estimate cannot be calculated as too many values were below the lower limit of quantification."}]}]},{"title":"Cycle 1 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"120.5","spread":"18.33"}]}]},{"title":"Cycle 1 5 hour post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"106.1","spread":"77.96"}]}]},{"title":"Cycle 2 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.072","spread":"121.6"}]}]},{"title":"Cycle 2 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"117.4","spread":"18.79"}]}]},{"title":"Cycle 3 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.262","spread":"111.2"}]}]},{"title":"Cycle 3 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"120.9","spread":"17.04"}]}]},{"title":"Cycle 4 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.014","spread":"60.69"}]}]},{"title":"Cycle 4 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"118.4","spread":"18.44"}]}]},{"title":"Cycle 6 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.046","spread":"67.91"}]}]},{"title":"Cycle 8 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.05","spread":"68.29"}]}]}]},{"type":"SECONDARY","title":"Serum Concentrations of Total Anti-HER2 Antibody","description":"Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for total anti-HER2 antibody.","populationDescription":"PK analysis set","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ug/mL","timeFrame":"An average of approximately 14 months","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"title":"Cycle 1 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"NA - Not calculated, estimate cannot be calculated as too many values were below the lower limit of quantification."}]}]},{"title":"Cycle 1 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"127.5","spread":"21.93"}]}]},{"title":"Cycle 1 5 hour post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"118.0","spread":"18.85"}]}]},{"title":"Cycle 2 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.866","spread":"148.7"}]}]},{"title":"Cycle 2 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"120.1","spread":"39.66"}]}]},{"title":"Cycle 3 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.582","spread":"126.4"}]}]},{"title":"Cycle 3 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"125.9","spread":"16.87"}]}]},{"title":"Cycle 4 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.974","spread":"84.38"}]}]},{"title":"Cycle 4 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"121.3","spread":"16.80"}]}]},{"title":"Cycle 6 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.083","spread":"95.47"}]}]},{"title":"Cycle 8 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.193","spread":"87.45"}]}]}]},{"type":"SECONDARY","title":"Serum Concentrations of DXd","description":"Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for DXd.","populationDescription":"PK analysis set","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"An average of approximately 14 months","groups":[{"id":"OG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"classes":[{"title":"Cycle 1 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"NA - Not calculated, estimate cannot be calculated as too many values were below the lower limit of quantification."}]}]},{"title":"Cycle 1 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.384","spread":"47.55"}]}]},{"title":"Cycle 1 5 hour post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.90","spread":"69.38"}]}]},{"title":"Cycle 2 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1751","spread":"119.4"}]}]},{"title":"Cycle 2 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.657","spread":"70.96"}]}]},{"title":"Cycle 3 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2423","spread":"110.6"}]}]},{"title":"Cycle 3 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.310","spread":"50.12"}]}]},{"title":"Cycle 4 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3226","spread":"53.71"}]}]},{"title":"Cycle 4 End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.139","spread":"51.35"}]}]},{"title":"Cycle 6 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3295","spread":"58.92"}]}]},{"title":"Cycle 8 Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3714","spread":"57.45"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"An average of approximately 16 months","eventGroups":[{"id":"EG000","title":"T-DXd Arm","description":"Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle.","deathsNumAffected":13,"deathsNumAtRisk":72,"seriousNumAffected":33,"seriousNumAtRisk":72,"otherNumAffected":72,"otherNumAtRisk":72}],"seriousEvents":[{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":72}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":72}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":72}]},{"term":"Covid-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":72}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":72}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":72}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":72}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":72}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":72}]},{"term":"Organising pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":72}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":72}]}],"otherEvents":[{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":23,"numAtRisk":72}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":11,"numAtRisk":72}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":72}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":72}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":72}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":72}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":26,"numAtRisk":72}]},{"term":"Covid-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":72}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":77,"numAffected":41,"numAtRisk":72}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":72}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":29,"numAtRisk":72}]},{"term":"Alpha hydroxybutyrate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":72}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":77,"numAffected":41,"numAtRisk":72}]},{"term":"Bile acids increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":5,"numAtRisk":72}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":9,"numAtRisk":72}]},{"term":"Bilirubin conjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":72}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":12,"numAtRisk":72}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":72}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":72}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":72}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":18,"numAtRisk":72}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":16,"numAtRisk":72}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":163,"numAffected":46,"numAtRisk":72}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":81,"numAffected":39,"numAtRisk":72}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":72}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":6,"numAtRisk":72}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":72}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":191,"numAffected":47,"numAtRisk":72}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":30,"numAtRisk":72}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":72}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":7,"numAtRisk":72}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":9,"numAtRisk":72}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":21,"numAtRisk":72}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":16,"numAtRisk":72}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":72}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":16,"numAtRisk":72}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":72}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":72}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":72}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":72}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":72}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":72}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":16,"numAtRisk":72}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":72}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":72}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":72}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":7,"numAtRisk":72}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":72}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":149,"numAffected":43,"numAtRisk":72}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Global Clinical Lead","organization":"AstraZeneca Clinical Study Information Center","email":"information.center@astrazeneca.com","phone":"1-877-240-9479"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-02-24","uploadDate":"2024-09-04T04:54","filename":"Prot_000.pdf","size":11794215},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-09-22","uploadDate":"2024-09-04T04:55","filename":"SAP_001.pdf","size":3310767}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-10-01","type":"ACTUAL"}}}},"interventionBrowseModule":{"meshes":[{"id":"C000614160","term":"trastuzumab deruxtecan"}]}},"hasResults":true}